Terms: = Leukemia AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Clinical Outcome
23 results:
1. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Pastore F; Gittinger H; Raab S; Tschuri S; Ksienzyk B; Konstandin NP; Schneider S; Rothenberg-Thurley M; Horny HP; Werner M; Sauerland MC; Amler S; Görlich D; Berdel WE; Wörmann B; Braess J; Hiddemann W; Tischer J; Herold T; Metzeler KH; Spiekermann K
Br J Haematol; 2023 Sep; 202(6):1165-1177. PubMed ID: 37455345
[TBL] [Abstract] [Full Text] [Related]
2. DUSP6 mediates resistance to jak2 inhibition and drives leukemic progression.
Kong T; Laranjeira ABA; Yang K; Fisher DAC; Yu L; Poittevin De La Frégonnière L; Wang AZ; Ruzinova MB; Fowles JS; Fulbright MC; Cox MJ; Celik H; Challen GA; Huang S; Oh ST
Nat Cancer; 2023 Jan; 4(1):108-127. PubMed ID: 36581736
[TBL] [Abstract] [Full Text] [Related]
3. HOXA9 has the hallmarks of a biological switch with implications in blood cancers.
Talarmain L; Clarke MA; Shorthouse D; Cabrera-Cosme L; Kent DG; Fisher J; Hall BA
Nat Commun; 2022 Oct; 13(1):5829. PubMed ID: 36192425
[TBL] [Abstract] [Full Text] [Related]
4. Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Stuckey R; Gómez-Casares MT
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068690
[TBL] [Abstract] [Full Text] [Related]
5. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic gene alterations and clonal changes in childhood B-ALL.
Erbilgin Y; Firtina S; Mercan S; Hatirnaz Ng O; Karaman S; Tasar O; Karakas Z; Celkan TT; Zengin E; Sarper N; Yildirmak ZY; Sisko S; Ozbek U; Sayitoglu M
Leuk Res; 2019 Aug; 83():106159. PubMed ID: 31228652
[TBL] [Abstract] [Full Text] [Related]
7. Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway.
Liu K; Wu Z; Chu J; Yang L; Wang N
Biomed Pharmacother; 2019 Jul; 115():108913. PubMed ID: 31054507
[TBL] [Abstract] [Full Text] [Related]
8. Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia.
Wang HQ; Jia L; Li YT; Farren T; Agrawal SG; Liu FT
J Cell Physiol; 2019 Aug; 234(8):13994-14006. PubMed ID: 30623437
[TBL] [Abstract] [Full Text] [Related]
9. Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea.
Azevedo AP; Silva SN; Reichert A; Lima F; Júnior E; Rueff J
Mol Med Rep; 2018 Dec; 18(6):5243-5255. PubMed ID: 30320340
[TBL] [Abstract] [Full Text] [Related]
10. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
11. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.
Luque Paz D; Chauveau A; Boyer F; Buors C; Samaison L; Cottin L; Seegers V; Férec C; Le Maréchal C; Gueguen P; Lippert E; Ianotto JC; Ugo V
Genes Chromosomes Cancer; 2017 May; 56(5):354-362. PubMed ID: 27997717
[TBL] [Abstract] [Full Text] [Related]
12. Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
[TBL] [Abstract] [Full Text] [Related]
13. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
[TBL] [Abstract] [Full Text] [Related]
14. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
[TBL] [Abstract] [Full Text] [Related]
15. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract] [Full Text] [Related]
16. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract] [Full Text] [Related]
17. Acquisition of a BCR-ABL1 transcript in a patient with disease progression from MDS with fibrosis to AML with myelodysplasia-related changes.
Park SJ; Lee HW; Jeong SH; Park JS; Kim HC; Seok JY; Kim HJ; Cho SR
Ann Clin Lab Sci; 2011; 41(4):379-84. PubMed ID: 22166509
[TBL] [Abstract] [Full Text] [Related]
18. Expression of p-jak2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.
Ikezoe T; Kojima S; Furihata M; Yang J; Nishioka C; Takeuchi A; Isaka M; Koeffler HP; Yokoyama A
Int J Cancer; 2011 Nov; 129(10):2512-21. PubMed ID: 21207414
[TBL] [Abstract] [Full Text] [Related]
19. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract] [Full Text] [Related]
20. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and jak2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract] [Full Text] [Related]
[Next]
